These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 3436066

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Aluminium chelation therapy in dialysis patients: evidence for inhibition of haemoglobin synthesis by low levels of aluminium.
    Altmann P, Plowman D, Marsh F, Cunningham J.
    Lancet; 1988 May 07; 1(8593):1012-5. PubMed ID: 2896867
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Pharmacokinetics and renal elimination of desferrioxamine and ferrioxamine in healthy subjects and patients with haemochromatosis.
    Allain P, Mauras Y, Chaleil D, Simon P, Ang KS, Cam G, Le Mignon L, Simon M.
    Br J Clin Pharmacol; 1987 Aug 07; 24(2):207-12. PubMed ID: 3620295
    [Abstract] [Full Text] [Related]

  • 25. Haemofiltration or haemodialysis in aluminium elimination?
    Sulkova S, Laurincova Z, Válek A.
    Nephrol Dial Transplant; 1991 Aug 07; 6 Suppl 3():3-5. PubMed ID: 1775263
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Removal of chelated aluminium during haemodialysis using polysulphone high-flux dialysers.
    Aarseth HP, Ganss R.
    Nephrol Dial Transplant; 1990 Aug 07; 5(11):942-4. PubMed ID: 2127830
    [Abstract] [Full Text] [Related]

  • 28. Aluminium interference in the treatment of haemodialysis patients with recombinant human erythropoietin.
    Casati S, Castelnovo C, Campise M, Ponticelli C.
    Nephrol Dial Transplant; 1990 Aug 07; 5(6):441-3. PubMed ID: 2122321
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P, Day JP.
    Clin Nephrol; 1985 Aug 07; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [Abstract] [Full Text] [Related]

  • 31. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P, Gmeiner R, Beck G, König P.
    Wien Med Wochenschr; 1987 Aug 15; 137(14-15):355-60. PubMed ID: 3673100
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Aluminum accumulation in children on chronic dialysis: predictive value of serum aluminum levels and desferrioxamine infusion test.
    Roodhooft AM, van de Vyver FL, D'Haese PC, van Acker KJ, Visser WJ, de Broe ME.
    Clin Nephrol; 1987 Sep 15; 28(3):125-9. PubMed ID: 3665205
    [Abstract] [Full Text] [Related]

  • 34. [Desferal treatment of aluminum poisoning; effect on serum concentrations of aluminum (Al), iron (Fe) and copper (Cu)].
    Günther K, Winnefeld K, Stein G, Sperschneider H, Schröter H, Fünfstück R.
    Z Urol Nephrol; 1986 Oct 15; 79(10):569-76. PubMed ID: 3811645
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Aluminium speciation in cerebrospinal fluid of acutely aluminium-intoxicated dialysis patients before and after desferrioxamine treatment; a step in the understanding of the element's neurotoxicity.
    Van Landeghem GF, D'Haese PC, Lamberts LV, Barata JD, De Broe ME.
    Nephrol Dial Transplant; 1997 Aug 15; 12(8):1692-8. PubMed ID: 9269651
    [Abstract] [Full Text] [Related]

  • 37. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Aug 15; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.